182

Kohli, M., Ferko, N., Martin, A., Franco, E. L., Jenkins, D., Gallivan, S., Drummond, M. (2007). Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. British Journal of Cancer, 96 (1), 143–50. https://doi.org/10.1038/sj.bjc.6603501

Kulasingam, S. L., Benard, S., Barnabas, R. V, Largeron, N., & Myers, E. R. (2008). Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Effectiveness and Resource Allocation, 6 (1), 4. https://doi.org/10.1186/1478–7547–6–4

Dasbach, E., Insinga, R., & Elbasha, E. (2008). The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG: An International Journal of Obstetrics & Gynaecology, 115 (8), 947–56. https://doi.org/10.1111/j.1471–0528.2008.01743.x